Join
Live feed
·
PRReleasevia Quantisnow
Fortress Biotech Inc. logo

Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease

ByQuantisnow·Wall Street's wire, on your screen.
FBIO· Fortress Biotech Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBIO (Fortress Biotech Inc.) and more on Quantisnow.